Upper Gastrointestinal Tract Lymphoma With Natalizumab: Evidence of Impaired Immune Surveillance?

In patients with multiple sclerosis who are treated with natalizumab, new, persistent, and/or upper gastrointestinal symptoms should prompt assessment for DLBCL (Tysabri, Biogen, RTP, NC).

Source: Neurology Clinical Practice - August 9, 2021 Category: Neurology Authors: Gomes, L., Watson, E., Smith, M. R., Morris, E., Boggild, M. Tags: All Oncology, Multiple sclerosis Case Source Type: research